6-(4-ARYLALKYLPIPERAZIN-1-YL)BENZODIOXANE AND 6-(4-ARYLALKYLPIPERAZIN-1-YL)CHROMANE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS

Disclosed are compounds of formula (I) or the pharmaceutically acceptable acid addition salts thereof, wherein: R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, tri...

Full description

Saved in:
Bibliographic Details
Main Authors THURKAUF, ANDREW, TRAN, JENNIFER, N
Format Patent
LanguageEnglish
French
Published 10.02.2000
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Disclosed are compounds of formula (I) or the pharmaceutically acceptable acid addition salts thereof, wherein: R1, R2, R3, R4 and R5 are the same or different and represent hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 alkylthio, hydroxy, amino, mono- or di(C1-C6)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; and X is oxygen, a bond, C1-C2 alkylene or methyleneoxy, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents. L'invention concerne des composés de la formule (I) ou des sels d'addition acides pharmaceutiquement acceptables desdits composés. Dans ladit formule, R1, R2, R3, R4 et R5 sont identiques ou différents et représentent hydrogène, halogène, alkyle C1-C6, alcoxy C1-C6, alkylthio C1-C4, hydroxy, amino, mono ou dialkylamino(C1-C6), cyano, nitro, trifluorométhyle ou trifluorométhoxy; et X est oxygène, une liaison, alkylène C1-C2, ou méthylèneoxy. Ces composés sont utiles pour le traitement et/ou la prévention de troubles neuropsychologiques, y compris, entre autres, la schizophrénie, la manie, la démence, la dépression, l'anxiété, le comportement compulsif, l'abus de substances psychoactives, les troubles moteurs de type parkinsonien et les troubles moteurs liés à l'usage de neuroleptiques antipsychotiques.
Bibliography:Application Number: WO1999US14426